



Family History as a Risk Factor for Herpes Zoster: is Herpes Zoster Risk Heritable?

Rebecca M Dahl, MPH, Rafael Harpaz MD, MPH
Centers for Disease Control and Prevention, Atlanta, GA

Contact Information:
Rafael Harpaz
RHarpaz@cdc.gov

BACKGROUND

- Almost 1 in 3 persons experience herpes zoster (HZ) during their lives, translating to ~1 million episodes annually in the U.S.; episodes can cause disabling and prolonged pain and other complications
- HZ is caused by reactivation of latent varicella zoster virus (VZV)
 - Both wild-type VZV (WT-VZV) and vaccine-strain VZV (VS-VZV) can reactivate, although the risk from VS-VZV appears to be much lower than that from WT-VZV^{1,2}
 - Virtually all persons are latently infected with either WT-VZV (i.e., recalled or unrecalled history of varicella) or VS-VZV (i.e., history of varicella vaccination), or both^{3,4}
- Risk factors for HZ are older age and immunosuppression, but these factors generally do not explain why some persons develop HZ and others do not
- Knowledge of HZ risk factors would provide clues for mechanisms underlying VZV reactivation, help explain the epidemiology of HZ, and could lead to better strategies for prevention
- Genetic predisposition is a potential risk factor for many illnesses. Several studies suggest HZ is heritable; all relied on self-report and were subject to recall and other bias⁵⁻¹⁰

STUDY OBJECTIVE

- We used data from a large national administrative database to assess whether medically-attended HZ is associated with HZ in family members
 - WT- and VS-VZV differ in many ways: age at "infection," size & route of inoculum, risk of reactivation, potential for misclassification, impact on HZ risk in contacts (via exogenous boosting); biologically, VZV strain may interact differently with heritability too. We therefore evaluated the associations by WT-VZV and VS-VZV strata as well.

METHODS

- Data Source:**
 - Claims data from Truven Health MarketScan® Databases, 1998-2014
 - Beneficiary and co-beneficiary data for millions of enrollees from public and private employers and health insurance plans
- Study Population:**
 - MarketScan enrollees
 - Sibling analysis: having ≥2 children in which oldest 2 are concordant for either WT-VZV or VS-VZV infection (definitions below)
 - Parent analysis: having ≥1 children (definition below)
 - Spouse analysis: having 1 spouse or if >1 spouse, the oldest spouse (definition below) and ≥1 children
- Study Definitions:**
 - Family: primary beneficiary with his or her co-beneficiaries
 - Child: a co-beneficiary with documented births (based on ICD-9 codes) between 1998 – 2014 (i.e., maximum age of 16 years)
 - Index: the oldest child in the family
 - Sibling: the second oldest child in the family
 - Parent: a primary beneficiary of ages 18 - 64
 - Spouse: the co-beneficiary of ages 18 - 64
 - HZ: defined using ICD-9 codes (053.XX) occurring between 1998-2014
 - VS-VZV infected: defined using CPT codes for varicella vaccination (90716, 90710) during 1998-2014
 - WT-VZV infected: defined by ABSENCE of CPT codes for varicella vaccination during 1998-2014
 - Family history of HZ: occurrence of HZ in the index child during 1998-2014
- Data Analysis**
 - Sibling analysis: HZ risk in sibling in families with vs. without family history of HZ
 - Parent analysis: HZ risk in parent in families with vs. without family history of HZ
 - Spouse analysis: HZ risk in spouse in families having parent with vs. without history of HZ
 - VZV strain analysis: impact of family history on HZ risk when children are infected with VS-VZV vs. WT-VZV
 - Relative risks (RR) with corresponding 95% confidence interval and p-values were calculated.

RESULTS

TABLE 1: Risk of HZ in siblings or parents when index child did or did not experience HZ*

	Index child HZ positive	Index child HZ negative	Relative Risk
	n	n	(95% CI, p-value)
Children WT-VZV infected			
Sibling (N=59,920)	76	59,844	28.5 (4.1, 198.0, p = 0.03)
Parent (N=1,457,046)	13,176	1,443,870	6.3 (4.5, 8.7, p < .0001)
Children VS-VZV infected			
Sibling (N=181,579)	323	181,256	12.6 (4.8, 33.5, p < .0001)
Parent (N=1,297,324)	24,298	1,273,026	2.1 (1.6, 2.7, p < .0001)
Children regardless of VZV			
Sibling (N=241,499)	399	241,100	14.7 (6.2, 35.2, p < .0001)
Parent (N=2,754,370)	37,474	2,716,896	3.3 (2.6, 4.0, p < .0001)

TABLE 2: Risk of HZ in spouses when parent child did or did not experience HZ (non-heritable controls)*

	Index child HZ positive	Index child HZ negative	Relative Risk
	n	n	(95% CI, p-value)
Spouses of parents			
Index child WT-VZV (N=1,032,871)	8,059	1,024,812	3.2 (2.8, 3.7, p < .0001)
Index child VS-VZV (N=1,011,085)	17,882	993,203	1.9 (1.8, 2.1, p < .0001)
Index child, all (N=2,043,956)	25,941	2,018,015	2.5 (2.3, 2.6, p < .0001)

* Abbreviations: HZ, herpes zoster; WT-VZV, wild-type varicella zoster virus; VS-VZV varicella vaccine-strain

- Siblings of HZ positive index children had 14.7 times the rate of HZ compared to those with HZ negative index children (Table 1)
- Parents of HZ positive index children had 3.3 times the rate of HZ compared to parents of HZ negative index children (Table 1)
- VZV strain influences the results: in the sibling analysis, the differences were not significant (p = 0.46) but in parent analysis they were (p < .0001)
- Spouses of HZ positive parents were at greater risk of HZ compared to spouses of HZ negative parents (when either VS- or WT-VZV infected index children) showing that our analysis may be influenced by non-heritable factors (Table 2)
- We looked among WT- and VS-VZV strata at calendar years of observation time and age of parents to see if differences were large and could be causing important bias
 - In sibling analysis, the median year of when observation time began (birth of index child) was 2009 vs. 2007 for WT- and VS-VZV strata, respectively, and in parent analysis the median years were 2010 and 2009, respectively (i.e., observation time similar across strata for these analyses)
 - The median age of parents was 31 and 32 years of age for WT- and VS-VZV strata, respectively (i.e., median age similar for these analyses)

LIMITATIONS

- Misclassification:
 - Family (child/sibling/parent/spouse) defined via co-beneficiary status
 - HZ (for establishing risk [family history] or outcome [HZ]):
 - HZ diagnosis is fairly specific, even for children*
 - HZ diagnosis is likely insensitive in children: it's mild (parents may ignore it; doctors may misdiagnose it). It's likely even less sensitive when due to VS-VZV: milder than HZ due to WT-VZV
 - VZV strain: varicella (WT-VZV) defined as lack of vaccination (~90% of varicella is not captured by MarketScan, vaccination is rarely missed). This could lead to misclassification:
 - VS-VZV as WT-VZV (if vaccine costs aren't charged for some reason)
 - VZV-negative children (neither varicella nor vaccine) as WT-VZV
 - Many of these sources of error would lead to conservative bias
- Differences in HZ risk within families may also be influenced by:
 - Shared non-heritable risk factors (environmental or behavioral)
 - VZV-strain: low HZ risk in VS-VZV positive siblings would increase attributable role of heredity (i.e., RR)
 - Shared healthcare access or health seeking behavior for HZ
 - Exogenous boosting by varicella exposure may reduce HZ risk yet only occur for WT-VZV, not VS-VZV
- On occasion HZ in parent or sibling would cause WT-VZV in a child

CONCLUSIONS

- Our analyses suggest that HZ risk is heritable
- Our methods clearly have limitations, however:
 - Many of misclassification errors would be conservative
 - We used controls to look for non-heritable effects; associations were seen but of lower magnitude suggesting (certainly not proving) that some of our observed associations are real
 - Given the factors noted above, our estimates are quite variable; we cannot use our results to derive a single estimate of association
- Heritability of HZ risk has important scientific and practical implications
- Our methods are based on medically-attended data
 - They complement recall-based studies, which are prone to bias
 - These methods provide an alternative approach to studying heritability for a wide variety of medical conditions

REFERENCES

- Weinmann S, et al. J Infect Dis. 2013 208(11):1859-68.
- Civen R, et al. Pediatr Infect Dis J. 2009 28(11):954-9.
- Kilgore PE, et al. J Med Virol. 2003;70 Suppl 1:S111-8.
- Reynolds MA, et al. Public Health Rep. 2010 125(6):860-9.
- Marin M, et al. Open Forum Infect Dis. 2016; 3(3).
- Hicks LD, et al. Archives of dermatology 2008; 144:603-8.
- Hernandez PO, et al. J Clin Virol 2011; 52:344-8.
- Lasserre A, et al. J Clin Virol 2012; 55:153-7.
- Ansar A, et al. J Res Health Sci 2014; 14:111-4.
- Gatti A, et al. J Med Virol 2010; 82:1007-11.

